Seven Fleet Capital Management LP — 13F Holdings & Portfolio

CIK 2092021 · latest 13F-HR filed 2026-08-17

Seven Fleet Capital Management LP manages $605.9M in 13F-reported U.S. long-equity assets across 114 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CGON (16.88%), TNGX (8.99%), TNGX (6.80%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 24 new positions and exited 43; 50 existing positions rose in reported value and 16 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$605.9M

Long-equity book

Holdings
114

Distinct positions

Period
2026-06-30

Filed 2026-08-17

Q/Q Activity
+24 / −43 / ↑50 / ↓16

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 65.1%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Jul 6, 2026.

Assets Under Management
$434.6M
Discretionary
$434.6M
Employees
4
Accounts
4
Phone
(650) 660-3618
Name Title / Status Ownership Type
Lim, Rod, Seung-Hwan ControlLIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP
since Feb 2025
50–75%Individual
Liu, Brian, Guan-Chyun ControlLIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER
since Feb 2025
25–50%Individual
SEVEN FLEET CAPITAL MANAGEMENT GP LLC ControlGENERAL PARTNER
since Feb 2025
Less than 5%Domestic Entity
Liu, Brian, Guan-Chyun Control
Indirect owner via SEVEN FLEET CAPITAL MANAGEMENT GP LLC
MANAGING MEMBER
since Feb 2025
75% or moreIndividual
Ownership & leadership changes · 1 filing with changes since Jun 30, 2026

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Jul 6, 2026 filing
  • ChangedLim, Rod, Seung-Hwan · title LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP / MEMBER OF SEVEN FLEET ADVISORS LLC → LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP
  • ChangedLiu, Brian, Guan-Chyun · title LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER / MANAGING MEMBER OF SEVEN FLEET ADVISORS LLC → LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER; ownership 50–75% → 25–50%
Jun 30, 2026 filing (earliest on record)
  • ListedLim, Rod, Seung-Hwan · LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP / MEMBER OF SEVEN FLEET ADVISORS LLC · 50–75% · control person
  • ListedLiu, Brian, Guan-Chyun · MANAGING MEMBER · 75% or more · indirect via SEVEN FLEET CAPITAL MANAGEMENT GP LLC · control person
  • ListedLiu, Brian, Guan-Chyun · LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER / MANAGING MEMBER OF SEVEN FLEET ADVISORS LLC · 50–75% · control person
  • ListedSEVEN FLEET CAPITAL MANAGEMENT GP LLC · GENERAL PARTNER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Seven Fleet Capital Management LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 CG ONCOLOGY INC CGON 156944100 $102.3M 16.88% 1,439,393 SH
2 TANGO THERAPEUTICS INC TNGX 87583X109 $54.4M 8.99% 1,909,593 SH
3 TANGO THERAPEUTICS INC TNGX 87583X109 $41.2M 6.80% 1,318,551 SH
4 REVOLUTION MEDICINES INC RVMD 76155X100 $36.4M 6.01% 194,363 SH
5 CG ONCOLOGY INC CGON 156944100 $31.7M 5.24% 446,843 SH
6 PHARVARIS N V PHVS N69605108 $16.7M 2.75% 482,524 SH
7 ABIVAX SA ABVX 00370M103 $14.8M 2.45% 111,334 SH
8 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $14.7M 2.42% 289,136 SH
9 LIQUIDIA CORPORATION LQDA 53635D202 $14.5M 2.40% 182,103 SH
10 MIRUM PHARMACEUTICALS INC MIRM 604749101 $12.9M 2.13% 110,393 SH
11 PHARVARIS N V PHVS N69605108 $10.1M 1.67% 291,977 SH
12 CYTOKINETICS INC CYTK 23282W605 $10.1M 1.66% 118,240 SH
13 TAYSHA GENE THERAPIES INC TSHA 877619106 $9.9M 1.64% 1,504,400 SH
14 REVOLUTION MEDICINES INC RVMD 76155X100 $8.9M 1.47% 47,666 SH
15 VERADERMICS INC MANE 922967104 $8.6M 1.42% 70,000 SH
16 ARRIVENT BIOPHARMA INC AVBP 04272N102 $8.6M 1.41% 246,606 SH
17 AVALO THERAPEUTICS INC AVTX 05338F306 $8.1M 1.34% 438,552 SH
18 TARSUS PHARMACEUTICALS INC TARS 87650L103 $7.9M 1.31% 117,067 SH
19 XENCOR INC XNCR 98401F105 $7.8M 1.29% 368,305 SH
20 ROIVANT SCIENCES LTD ROIV G76279101 $7.8M 1.29% 220,126 SH
21 CENTURY THERAPEUTICS INC IPSC 15673T100 $7.2M 1.19% 2,947,826 SH
22 AXSOME THERAPEUTICS INC AXSM 05464T104 $7.1M 1.16% 28,826 SH
23 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $7.0M 1.15% 148,647 SH
24 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $6.2M 1.03% 226,415 SH
25 AVALO THERAPEUTICS INC AVTX 05338F306 $6.1M 1.01% 332,213 SH
26 LIQUIDIA CORPORATION LQDA 53635D202 $5.9M 0.98% 74,500 SH
27 COGENT BIOSCIENCES INC COGT 19240Q201 $5.7M 0.94% 147,510 SH
28 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $5.7M 0.94% 206,732 SH
29 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $5.6M 0.92% 45,400 SH
30 EDITAS MEDICINE INC EDIT 28106W103 $4.3M 0.71% 1,330,500 SH
31 DIANTHUS THERAPEUTICS INC DNTH 252828108 $4.3M 0.70% 43,672 SH
32 MINERVA NEUROSCIENCES INC NERV 603380205 $4.2M 0.69% 754,397 SH
33 DAMORA THERAPEUTICS INC DMRA 36322Q206 $4.0M 0.66% 154,430 SH
34 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $3.9M 0.64% 76,250 SH
35 ERASCA INC ERAS 29479A108 $3.9M 0.64% 210,346 SH
36 SUTRO BIOPHARMA INC STRO 869367201 $3.8M 0.63% 159,118 SH
37 CENTURY THERAPEUTICS INC IPSC 15673T100 $3.4M 0.57% 1,400,000 SH
38 DAMORA THERAPEUTICS INC DMRA 36322Q206 $3.4M 0.56% 130,000 SH
39 RELAY THERAPEUTICS INC RLAY 75943R102 $3.3M 0.55% 178,222 SH
40 ASCENDIS PHARMA A/S ASND K08588103 $3.2M 0.52% 11,869 SH
41 SAGIMET BIOSCIENCES INC SGMT 786700104 $3.1M 0.51% 403,545 SH
42 ZAI LAB LTD ZLAB 98887Q104 $2.9M 0.48% 136,016 SH
43 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $2.7M 0.44% 714,000 SH
44 MADRIGAL PHARMACEUTICALS INC MDGL 558868105 $2.7M 0.44% 4,973 SH
45 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $2.6M 0.43% 70,164 SH
46 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $2.5M 0.42% 7,540 SH
47 RELMADA THERAPEUTICS INC RLMD 75955J402 $2.4M 0.40% 348,265 SH
48 EUPRAXIA PHARMACEUTICALS INC EPRX 29842P105 $2.2M 0.37% 334,785 SH
49 AGIOS PHARMACEUTICALS INC AGIO 00847X104 $2.1M 0.35% 56,900 SH
50 XENON PHARMACEUTICALS INC XENE 98420N105 $2.1M 0.34% 33,300 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-17 $605.9M 114 0001013594-26-000921
2026-03-31 2026-06-04 $318.3M 115 0001013594-26-000652
2026-03-31 2026-05-15 $315.1M 114 0001013594-26-000616
2025-12-31 2026-04-02 $147.8M 87 0001013594-26-000420
2025-12-31 2026-02-26 $131.5M 87 0001013594-26-000305
Filer Information
Address
960 SAN CLEMENTE WAY
MOUNTAIN VIEW, CA 94043
Phone
(650) 660-3618
Filing Manager
Seven Fleet Capital Management LP
MOUNTAIN VIEW, CA
Signatory
Brian Liu
Managing Member of the General Partner